Virtium Acquires System-on-Module (SOM) Specialist Embedded Artists to Add Edge AI, Industrial Computing and Connectivity Capabilities
Strategic move expands Virtium’s offerings to include compute, AI accelerator, memory, storage, connectivity modules and software solutions for industrial OEMs worldwide
Virtium, a trusted provider of industrial-grade memory and storage solutions, today announced it has acquired Embedded Artists AB, headquartered in Sweden, a renowned developer of specialized compute, AI accelerator and connectivity modules for Edge AI and industrial applications. This acquisition accelerates Virtium’s strategic expansion into the rapidly evolving edge computing, artificial intelligence, and high-performance industrial computing markets.
Embedded Artists, with more than 20 years of expertise, is a recognized leader in the design of system-on-module (SOM), AI accelerator modules, and connectivity solutions such as Wi-Fi and Bluetooth. Embedded Artists’ cutting-edge technology in Edge AI computing complements Virtium’s product portfolio, enabling the company to deliver even more innovative solutions to its customers across diverse industries.
Simplify, Accelerate, and Reduce the Cost of Embedded Systems Development
Virtium now offers a full line of compute, memory, storage, and connectivity modules, along with software solutions, tailored for industrial OEMs worldwide. Customers will benefit from the combined expertise of both companies, gaining access to a wider range of high-reliability, industrial-grade solutions that reduce the complexity, time, and cost of deploying advanced computing systems.
"By integrating Embedded Artists’ expertise and products in edge computing and connectivity with our portfolio of industrial-grade memory and SSDs, Virtium reaches a significant milestone in our vision to simplify, accelerate, and reduce the cost of embedded systems development," said Phu Hoang, CEO of Virtium. "The development of Edge AI computing systems is becoming increasingly complex in terms of design and component selection. Customers need flexible and modular solutions that are easy to choose and integrate, enabling them to mitigate component shortages and minimize changes throughout the long-term lifecycle deployment. Our solutions are designed to meet these needs, driving efficiency and fostering innovation."
Anders Rosvall, CEO of Embedded Artists, shared his enthusiasm: “Joining forces with Virtium will leverage our extensive expertise in hardware and software architecture, design resources, and industry experience to provide complete solutions that include memory and storage. Our customers will continue to receive the exceptional support and services they expect, while also benefiting from Virtium's well-established manufacturing infrastructure, which delivers high-volume production with top-tier quality. Embedded Artists products are now available worldwide, with manufacturing based in the USA and an expanded facility in Vietnam to support our growth and global reach.”
Shane McGregor, Court Square Partner, remarked, "This acquisition significantly strengthens Virtium's position as a leading provider of industrial Edge AI system solutions in rapidly growing sectors. The platform will continue to evolve, enabling further expansion and acquisition opportunities within the industrial Edge AI computing space."
About Virtium
Virtium is a trusted leader in the design and manufacturing of high-reliability industrial storage, memory solutions, and now includes compute, AI accelerators, connectivity modules, and software solutions. With over 25 years of experience, Virtium has earned a reputation for delivering high-quality products that meet the demanding requirements of global customers in industries such as networking, telecommunications, industrial OEMs, and embedded markets. Virtium’s commitment to innovation, long-term product availability, and customer support has made it a preferred partner for companies requiring mission-critical Edge AI system solutions.
About Embedded Artists
Embedded Artists develops and manufactures a wide range of Computer-on-Modules and Wi-Fi/Bluetooth modules that can be easily integrated into end-products. This simplifies the task for companies to use more advanced processors, microcontrollers, and wireless solutions in their applications. Embedded Artists is an NXP Gold member of the NXP Partner Program and close partner to Murata.
For more information, visit Virtium website and Embedded Artists website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241210541662/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom